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Abstract Clostridium Difficile Infection (CDI) has registered a dramatically increasing incidence in the 
general population over the past decades. Nowadays, Clostridium Difficile is the leading cause of 
hospital-acquired diarrhea in Europe and North America. Liver cirrhosis is the final stage of any 
chronic liver disease (CLD). The most common causes are chronic hepatitis C or B and viral co-
infections, alcohol misuse, and nonalcoholic fatty liver disease (NAFLD). 
CLD and cirrhosis are listed among the ten leading causes of death in the US. Cirrhosis due to 
any etiology disrupts the homeostatic role of the liver in the body. Cirrhosis-associated immune 
dysfunction (CAID) leads to alterations in both inherited and acquired systemic and local liver 
immunity. CAID is caused by increased systemic inflammation and immunodeficiency and it is 
responsible for 30% of mortality rates all over the world. 
Clostridium Difficile infection frequently affects patients suffering from liver cirrhosis because 
of the high number of prolonged hospitalizations, regular use of antibiotics for the prevention or 
treatment of SBP, proton pump inhibitor (PPI) use, and an overall immunocompromised state. 
Clostridium Difficile is a Gram-positive bacterium responsible for the high morbidity and mortality 
rates in patients with cirrhosis, with an essential increase in a 30-day mortality. 
Keywords  clostridium difficile, liver cirrhosis, anaerobic infection, immune dysfunction 
Highlights ✓ Patients with liver cirrhosis are characterized by alterations of inherited and acquired 
immunosuppression, being an easy target for Clostridium Difficile, which is associated 
with significant morbidity and mortality. 
✓ The latest guideline treatment recommendations for an initial episode of Clostridium 
Difficile have changed, either vancomycin or fidaxomicin now currently chosen over 
metronidazole. 
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Introduction 
Clostridium Difficile represents a common infection in 
healthcare settings, being responsible for severe diarrhea 
(1-3). Hall and O'Toole first isolated C. Difficile from the 
stool of a healthy infant. The given name of the bacterium 
resulted from the difficulty of isolation and culture by 
using the available methods at the time. The secondary 
pseudomembranous colitis associated with C. Difficile 
infection was first described in 1893. In 1978, researchers 
associated C. difficile with antibiotic-associated diarrhea 
(4). 
The highest incidence is among those aged over 65 
years, being more prevalent among females and whites. 
Clostridium Difficile is the most common pathogen in 
nosocomial and antibiotic-associated diarrheal diseases. It 
can also be a community-acquired Clostridium Difficile 
infection in patients with no risk factors (5). The frequency 
of the Clostridium Difficile infection (CDI) and its 
increased morbidity, which is associated with a prolonged 
duration of treatment, leads to a significant increase in 
hospital treatment costs. 
Cirrhosis occurs when regenerative nodules surrounded 
by fibrous bands replace the healthy liver tissue. This 
deranged histologic architecture is responsible for the 
portal hypertension and end-stage liver disease. The cause 
of cirrhosis is easy to recognize by making a minute history 
anamnesis, and also by combining the serologic and 
histologic evaluation. According to the geographic area, 
the leading cause responsible for the occurrence of liver 
cirrhosis is different. For example, abusive alcohol intake 
and hepatitis C infection are the most common causes of 
liver cirrhosis in developed countries, while hepatitis B is 
common in endemic areas such as Asia and sub-Saharan 
Africa. Nonalcoholic steatohepatitis (NASH) in obese and 
diabetic patients is responsible for the development of liver 
cirrhosis when there is no other apparent cause. Knowing 
the etiology is essential in order to apply the correct 
treatment and to predict both evolution and prognosis (6-
9). 
The Clostridium Difficile infection is becoming an 
increasingly incident disease, with the highest risk of 
infection occurring in hospitalized patients and with 
unusually high mortality in immunosuppressed patients, 
responsible for high morbidity and mortality rates, being 
a substantial financial burden for healthcare providers 
(10, 11).  
Discussions 
Pathogenesis 
Clostridium Difficile is an anaerobic, Gram-positive, 
spore-forming bacillus, which may be part of the normal 
intestinal microbiota in healthy newborns. The 
microorganism, first described in 1935, is transmitted 
through the oral-fecal route. CDI affects tissues through 
toxin production. The pathogenesis strains of C. Difficile 
produce two exotoxins: A (enterotoxin) and B (cytotoxin). 
The pathogenic effect involves several steps. Before 
toxin production, which is essential for gut damage and 
diarrhea occurrence, the germination of C. Difficile spores 
is required. The survival in spore formula provides 
resistance to antibiotics and is responsible for recurrent 
disease following the eradication treatment (12-14). 
The lumen of the colon is anoxic, thus creating the 
perfect environment for anaerobic bacteria such as 
Clostridium Difficile to survive and moreover, to 
proliferate and produce toxins. The bacterial spores resist 
against oxygen, heat, and common ethanol-based 
disinfectants, which favor proliferation (15). 
Many efforts have been made throughout the years to 
understand Clostridium Difficile sporulation, but 
understanding is still currently limited. Commonly, C. 
Difficile acts like a nosocomial pathogen, the source of 
infection being contaminated by humans or healthcare 
facilities. Spores are resistant to gastric acidity and 
germinate into the vegetative form in the intestine. 
Hospitalized patients may acquire CDI by the ingestion of 
spores or vegetative bacteria from the environment or the 
hands of healthcare personnel (16). 
Liver cirrhosis is a progressive disease, evolving from 
an asymptomatic, compensated stage to a complicated, 
decompensated one, usually associated with poor 
prognosis. Any type of infection can decompensate a 
compensated liver cirrhosis and lead to complications of 
cirrhosis such as upper digestive bleeding, ascites, 
hepatorenal or hepatopulmonary syndrome, or hepatic 
encephalopathy, all of which have high mortality rates.  
Regardless of its etiology, cirrhosis, as the end stage of 
chronic liver disease, commonly evolves to a syndrome 
called cirrhosis-associated immune dysfunction syndrome 
(CAIDS). Abnormalities of the immune function in 
patients with liver cirrhosis are caused by the 
immunodeficiency and systemic inflammation that occur 
in cirrhosis. The syndrome of decreased immunity is a 
combination of different immunological mechanisms and 
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reactions which result from an advanced stage of the liver 
disease (17, 18). The local impaired immune response is 
responsible for not recognizing antigens; in this way, the 
effector mechanisms are improper (19). An imbalance 
between the pro-inflammatory and anti-inflammatory 
mechanisms occurs and the activation of the immune 
system is inefficient (20, 21). 
Clinical entities such as pneumonia, spontaneous 
peritonitis, skin inflammatory diseases, infections of the 
urinary system, fungal infections, and C. Difficile diarrhea 
should be promptly recognized and treated (22-24). By 
adopting this approach, the risk of complications decreases 
and both prognosis and outcome can be improved (25, 26). 
Risk factors 
Cirrhotic patients represent a particular category of 
patients, their disease carrying many potential risk factors 
for the development of CDI, especially in decompensated 
stages of the illness (27, 28). Clostridium Difficile 
infection has an increased prevalence as a second infection 
in cirrhotic patients. 
Many studies confirm the idea that intercurrent 
infections in patients with liver cirrhosis, especially in 
advanced stages (Child Pugh B or C), increase mortality by 
4 times. One third of patients die within the first month 
after the infection and another third die within the first 12 
months.  This category of patient is at increased risk of 
developing Clostridium Difficile colitis for many reasons, 
most of which can be explained briefly as follows. 
The use of antibiotics remains the most widely 
recognized risk factor for the development of C. Difficile 
infection. Cirrhotic patients often require prophylactic or 
curative antibiotic therapy, for example Norfloxacin, 
which is commonly used in the outpatient prophylaxis of 
spontaneous bacterial peritonitis (SBP), and quinolones or 
third-generation cephalosporins used in case of upper 
digestive bleeding. Also, these patients are more frequently 
cared for in an intensive care unit (ICU) and antibiotics are 
prescribed during their hospitalization (5). 
Almost all antibiotics can disrupt the normal gut 
microbiota, allowing Clostridium Difficile to spread and 
produce toxins. The risk of infection is increased directly 
proportional to the duration and quantity of antibiotics 
administered, but cases of infection have been reported 
even after a single dose administration (29). 
Rifaximin is a routine medication in the prevention of 
hepatic encephalopathy, as well as Lactulose. Rifaximin 
has a broad antimicrobial spectrum, including aerobes and 
anaerobes, Gram-positive and Gram-negative bacteria. 
According to literature data, when administered orally, 400 
mg twice per day, 10 days a month, it seems to be useful in 
C. Difficile infection as well, because it is virtually non-
absorbed and its activity occurs mostly within the intestinal 
lumen (30). Recent studies have revealed that both 
Rifaximin and Lactulose are associated with a reduced risk 
of developing CDI in hospitalized patients, whether or not 
they received other antibiotics. This phenomenon could be 
possible due to the fact that Lactulose reduces the 
production of short chain fatty acids and Rifaximin 
suppresses the enteral ammonia, with those effects having 
a protective effect by reducing the suitable conditions for 
Clostridium Difficile proliferation (31). However, 
resistance was noted. There are few studies regarding the 
risk of developing CDI in cirrhotic patients receiving 
Rifaximin, so clinicians should also be aware of this risk. 
Other potential risk factors in cirrhotic patients could 
be frequent and prolonged hospitalization periods which 
place the patient in a suitable environment for high 
exposure to CDI, proton pump inhibitors (PPI) utilization 
for peptic ulcers, ligation-induced ulcers or 
gastroesophageal reflux, advanced age associated with a 
multitude of comorbidities, malnutrition, cancer, antiviral 
treatments, and the overall immunocompromised state. As 
an observation, C. Difficile infections were more 
frequently detected in patients with alcoholic liver cirrhosis 
(32, 33). 
C. Difficile infections in patients with liver cirrhosis 
worsen the disease outcome; however, the overall mortality 
is not affected if appropriate diagnosis is made and suitable 
treatments are applied (34). Severe hypoalbuminemia and 
intensive care admission are predictors of increased 
mortality in cirrhotic patients with C. Difficile infection 
(11, 13). 
Treatment 
The diagnosis of C. Difficile infection takes into 
account clinical manifestations such as diarrhea - Bristol 
stool chart types 5–7, meaning more than three stools 
within 24 hours, accompanied by abdominal pain and 
systemic signs and symptoms such as fever, hypotension, 
or shock, but also a positive result of C. Difficile and/or its 
toxins in laboratory testing. Antibiotic therapy is the first 
choice for CDI, and specific guideline recommendations 
are based on the severity of the disease. 
The latest guideline treatment recommendation for an 
initial episode of mild to moderate Clostridium Difficile 
infection has changed, recent data suggesting an overall 
superiority of vancomycin over metronidazole. The oral 
formula of vancomycin in dosages of 125 mg four times 
per 24 hours for 10–14 days is preferred. In case of 
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recurrence, fidaxomicin 200 mg twice a day for ten days is 
preferred, but this medication is not available in Romania 
(28). 
For severe or fulminant cases, metronidazole 500 mg 
intravenously three times a day for 10–14 days combined 
with vancomycin 125 mg orally four times a day for 10–14 
days is recommended. 
The first recurrence requires the same treatment as the 
initial episode, but for the second or further recurrences, 
vancomycin in a pulsed regimen and fecal microbiota 
transplantation (FMB) are recommended (21). 
Fecal microbiota transplantation for an initial episode 
has not yet been sufficiently studied, but it is considered to 
be the most effective, inexpensive, and quickest solution 
for a recurrent infection. Despite ongoing studies, donor 
selection and screening, along with timing and route of 
transplantation remain important issues regarding FMB 
(35). 
A unified standard to screen donors is not available at 
the moment. Summarized donor criteria include being able 
to give written consent, being over 18 years or parental 
consent and child assent in the case of minors. The 
exclusion criteria are: drug use, history of incarceration, 
history of chronic gastrointestinal disease, autoimmune, 
atopic diseases, chronic neurologic disorders, obesity or 
severe malnutrition, malignancy or ongoing 
immunosuppressive therapy/chemotherapy, and strong 
family history of colorectal neoplasia; in the past 12 
months: blood transfusions, unprotected intercourse, and 
known interaction with HBV, HCV, HIV; in the past 6 
months: tattoos, piercings, and international tropical 
travels; in the past 3 months: antibiotic use and smallpox 
vaccine; and in the past month: diarrhea, emesis, and fever 
or family members showing signs of gastrointestinal 
infection. There are both mandatory and optional blood 
tests in the guidelines. The required ones are HBV surface 
antigen, HCV antibody, HAV IgM, HIV 1+2, syphilis 
tests; and optionally, patients could be tested for HTLV 
1+2, BK virus, Epstein-Barr virus, HBV core antibody, and 
HBV surface antibody. Blood tests such as complete blood 
counts, liver and kidney tests could be useful, but are not 
compulsory. Mandatory stool testing includes Clostridium 
Difficile, and then bacterial culture for Salmonella, 
Yersinia, Shigella, Campylobacter and E. Coli; parasite 
and ovum examination, and additional tests depending on 
the case such as Giardia, Rotavirus, Listeria spp, Vibrio 
spp, Isospora, Cyclospora, Helicobacter Pylori, Entamoeba 
histolytica (36, 37). 
When choosing the treatment for the C. Difficile 
infection associated with liver cirrhosis, severe illness, 
cachexia related to impaired protein balance, and 
complications limit the treatment options and efficacy (31). 
Conclusions 
C. difficile is a Gram-positive bacterium living in many 
resistant forms, overwhelming harsh environments and 
conventional sterilization options. It is a nosocomial 
pathogen, the source of infection is infected by humans and 
contaminated hospital or medical devices. 
Cirrhotic patients are more frequently cared for in an 
intensive care unit (ICU) and they are prescribed 
antibiotics during their hospitalization; spontaneous 
bacterial peritonitis (SBP), prophylactic or curative 
antibiotic use; the administration of antibiotics in variceal 
upper digestive bleeding, all of these being particular CDI 
development risk factors in patients with liver cirrhosis. 
The Clostridium Difficile infection is becoming an 
increasingly incident disease, with the highest risk of 
infection occurring in hospitalized patients and with 
unusually high mortality in immunosuppressed patients. C. 
Difficile infections in patients with liver cirrhosis are 
associated with a significant increase of a 30-day mortality, 
but not overall mortality. Liver failure producing severe 
hypoalbuminemia and ICU admissions worsen the 
mortality rates and prognosis in cirrhotic patients infected 
with C. Difficile. However, it is difficult to fix the mortality 
rates attributable to C. Difficile infection in a group of 
patients with severe comorbidities, such as the liver 
cirrhosis group. 
During the past decade, understanding the pathogenesis 
of Clostridium Difficile infection has substantially 
increased, thus leading to new therapeutic approaches. 
Fecal microbiota transplantation is considered a giant step 
forward, because it is indisputably effective as a curative 
treatment. We thus predict that CDI could be the first 
infection efficiently treated with bacteriotherapy. 
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